LQV Branded Vial
Retatrutide
Includes syringes and alcohol pads with every vial shipment.
Retatrutide
(RTA)
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. By engaging three metabolic pathways, it represents the next generation of weight management therapies with the potential for greater efficacy in both weight loss and metabolic improvement.
How It Works
Retatrutide activates GLP-1 receptors to suppress appetite, GIP receptors to enhance insulin response and fat metabolism, and glucagon receptors to increase energy expenditure and promote fat breakdown. This triple mechanism addresses weight management from multiple physiological angles simultaneously.
Key Benefits
Who It Is For
Adults with significant weight management goals who are candidates for advanced pharmacological therapy. Ideal for individuals seeking cutting-edge treatment options under close medical supervision. Requires thorough medical evaluation and ongoing monitoring.
Common Side Effects
Common side effects include nausea, diarrhea, vomiting, and decreased appetite. Due to the glucagon receptor activity, some patients may experience increased heart rate or mild blood sugar fluctuations. Serious adverse events are under continued study. All risks are reviewed during consultation.
Other GLP-1 Therapies
GLP-1 Therapy
Semaglutide
(SMA)
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management and now widely used for weight management. It helps reduce appetite, slow gastric emptying, and promote sustainable weight loss when combined with lifestyle modifications.
From $299
GLP-1 Therapy
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. It has demonstrated significant efficacy in clinical weight loss trials and offers enhanced metabolic benefits compared to single-receptor therapies.
From $399
GLP-1 Therapy
Cagrilintide
Cagrilintide is a long-acting amylin analog that enhances satiety signaling. It works through a distinct mechanism from GLP-1 therapies, targeting the amylin pathway to help patients feel full sooner and reduce overall food intake.
From $349
Frequently Asked Questions
A therapy that mimics natural gut hormones involved in appetite and blood sugar regulation.
Yes. Medical evaluation and monitoring are required for all GLP-1 therapies.
Yes, following medical review and protocol setup.
Yes. Use the Speak To Our Medical Team tab to submit a form and request a consultation.
Prescription therapies require medical evaluation and supervision. Results vary. Side effects and risks are discussed during consultation.